sameAs
P3781
Lesinurad Tablet BioequivalenceCombination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and FebuxostatCombining Lesinurad With Allopurinol in Inadequate RespondersLesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase InhibitorsA Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal ImpairmentOpen-Label Lesinurad Monotherapy Extension Study in GoutMetformin and Furosemide Drug-Drug Interaction StudyLesinurad Tablet Relative BioavailabilityAntacid Interaction StudyBioavailability of Lesinurad and Intravenous [14C]LesinuradLesinurad and Febuxostat Combination Extension Study in GoutAllopurinol Combination StudyGout Dose Response StudyLesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.Lesinurad/Allopurinol 200/300 FDC Tablets BioavailabilityLesinurad Interaction Study With RanitidineNSAID Drug Interaction StudySingle and Multiple Dose Study in JapaneseLesinurad/Allopurinol 200/300 FDC Tablets BioequivalenceLesinurad and Allopurinol Combination Extension Study in GoutPost-Authorisation Safety Study of LesinuradCombining Lesinurad With Allopurinol in Inadequate Responders (2011-12-31)
P4844
Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinolNew medications in development for the treatment of hyperuricemia of gout.Investigational drugs for hyperuricemia.Pharmacokinetics, pharmacodynamics, and safety of lesinurad, a selective uric acid reabsorption inhibitor, in healthy adult males.[Gout: what's new?].Reassessing the Safety Profile of Lesinurad in Combination with Xanthine Oxidase Inhibitor TherapyMoving the Needle: Improving the Care of the Gout PatientPharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemiaEmerging therapies for gout
P921
Q61894606-90C07FC1-D88A-4D6D-99B3-D97F80660419Q61956138-D9BCB7B5-F485-4288-BB65-E342B4CF7E32Q61956237-5F454374-6C87-423E-872F-41CC55AAA064Q61956541-5B696877-2C9B-4F78-AC49-8CF099BF62EAQ63013502-4A1A2625-5E34-4929-952F-07DE400500D2Q63838961-9F4178EF-C41A-4AB6-9EE6-C3D2992CD9DBQ64349500-FFD94FAF-A880-44F8-8286-632946191B4DQ64352033-81FCD257-184A-4C20-B47D-C9C5B3E3E9FCQ64352383-73C3676C-72A4-495F-B587-D0B2D8C1F128Q64375557-30E27797-4780-4472-8701-0A36B61A7F10Q64626446-4E47A0E8-ACD3-4234-9D4A-464CE26CDDB3Q64661114-C246C2F6-5AFD-4A09-9ADE-7765C2FFE914Q64695888-8020FD34-5B83-4797-A8EE-3E6AAB3F82DCQ64819384-CF13067A-E183-4A98-96DD-A4D4FB3A8E3AQ65316085-565C10D5-D114-4A4A-AD2B-87B9C94BD92BQ65361823-7B0964EB-EBF7-4614-B01B-2B606E7848CEQ65362099-B48A1E6E-1E71-4A9F-8935-3322187F80C2Q65371505-B8648285-08B0-482C-8E28-84A85F66F185Q66084103-8B9C16C0-F7F9-4629-A119-CF5DF61398AEQ66344569-10082023-8F24-4190-834B-8DA7D3D6B82FQ74286591-EA752561-2F06-40BA-B371-B6CA61EE7C86Q86169926-8C53AFA6-A5A0-4FDE-AD53-C64824F21EE1
P4844
Q24658504-CD676C13-49C3-4654-8567-D6128C03BD4DQ38324954-AF3C75A7-8C00-4930-989A-1A30D5D59BF0Q38527441-415D77E2-CCD2-4C4D-AEA0-241F5C0910E2Q41295678-330B8BF3-9906-4C40-8F59-668DE4DC2207Q41594296-8B588F5B-668E-4B6A-B54D-2322F4A53A8DQ64231007-A5D86127-61C6-4A31-822B-7BC8A3A422AFQ64248223-88680BCF-B963-49CE-92BD-5844A66373E3Q87257185-10A355A1-7067-44DA-81BE-00CB728A8353Q87616328-90053207-A801-4AC3-AD86-B8019976DFCD
P921
description
Pharmaceutical drug for the treatment of gout
@en
chemická sloučenina
@cs
chemische Verbindung
@de
chemische verbinding
@nl
component quimic
@oc
compost químic
@ca
composto chimico
@it
composto químico
@gl
composto químico
@pt
composto químico
@pt-br
name
Lesinurad
@en
Lesinurad
@fr
Lesinurad
@pt
Lesinurad
@vi
type
label
Lesinurad
@en
Lesinurad
@fr
Lesinurad
@pt
Lesinurad
@vi
altLabel
RDEA 594
@en
RDEA-594
@en
RDEA594
@en
Zurampic®
@en
lesinurad
@en
prefLabel
Lesinurad
@en
Lesinurad
@fr
Lesinurad
@pt
Lesinurad
@vi
P31
P486
P592
P6366
P661
P662
P665
P683
P1579
P2067
P2115
N0000192752
P2275
lesinurad
@en
P231
878672-00-5
P232
P233
C1CC1C2=CC=C(C3=CC=CC=C23)N4C(=NN=C4Br)SCC(=O)O
P234
1S/C17H14BrN3O2S/c18-16-19-20- ...... h1-4,7-8,10H,5-6,9H2,(H,22,23)
P235
FGQFOYHRJSUHMR-UHFFFAOYSA-N
P2566
100.216.089